Reward your friends, Reward yourself!
Refer a Friend and you both save: When your friends subscribe, they get their second month of unlimited use free, and you get TWO months’ free unlimited use! We appreciate our customers who introduce us to new customers, and we want to say thank you with this bonus.
Refer easily: The link below will launch an email to us so you can send us the information we need to contact your friend and introduce them to PreViser.
Refer a friend now!
You may wish to alert your referred friends that we will be contacting them, so they’ll know what to expect.
Refer with confidence: We appreciate you sharing PreViser with your friends and colleagues, and we will protect their details just as we protect yours – we never share names and contact info (without first getting your express permission for a specific purpose, such as a reference).
Refer as often as you’d like: You can save with every referral, and there's no limit to how many friends you can refer! The savings add up fast.
Monday, June 15, 2009
Monday, May 18, 2009
PreViser lecture at Business of Dentistry 2009
PreViser CEO Carl Loeb will be presenting next month at the Dentrix Users' Conference, "Business of Dentistry."
Program title: "Evidence Based Optimization of the Hygiene Department"
Date: Friday June 12, 2009
Course Description:
PreViser Corporation has developed proprietary methods for the precise calculation of periodontal disease risk and severity, as well as oral cancer and caries risk. The use of this technology, now integrated with the Dentrix system, has the potential to significantly increase practice productivity while dramatically enhancing patient outcomes. With PreViser, a patient population is easily characterized by their oral care needs, and when implemented fully, allows a dental practice to focus practice resources on the patients at highest needs, and consequently of greatest economic value to the practice.
Mr. Loeb will address the practical aspects of the use of the PreViser system on the modern dental office. Impacts on patient compliance, case acceptance, loyalty, insurance reimbursement, productivity and clinical outcomes will be discussed in depth with practical suggestions on the best ways to take advantage of a powerful new capability offered to Dentrix users.
More information on the conference is at: http://www.businessofdentistry.com/index.html
Not a Dentrix user, or not attending the conference? We can schedule a webcast to go over this material with you - contact us to request this.
Program title: "Evidence Based Optimization of the Hygiene Department"
Date: Friday June 12, 2009
Course Description:
PreViser Corporation has developed proprietary methods for the precise calculation of periodontal disease risk and severity, as well as oral cancer and caries risk. The use of this technology, now integrated with the Dentrix system, has the potential to significantly increase practice productivity while dramatically enhancing patient outcomes. With PreViser, a patient population is easily characterized by their oral care needs, and when implemented fully, allows a dental practice to focus practice resources on the patients at highest needs, and consequently of greatest economic value to the practice.
Mr. Loeb will address the practical aspects of the use of the PreViser system on the modern dental office. Impacts on patient compliance, case acceptance, loyalty, insurance reimbursement, productivity and clinical outcomes will be discussed in depth with practical suggestions on the best ways to take advantage of a powerful new capability offered to Dentrix users.
More information on the conference is at: http://www.businessofdentistry.com/index.html
Not a Dentrix user, or not attending the conference? We can schedule a webcast to go over this material with you - contact us to request this.
Wednesday, May 6, 2009
Graph of Tooth Loss over 15 years by PreViser Risk Score
This graph shows the percentage of teeth lost over a 15-year period, absent treatment, as predicted by PreViser risk scores (see our research published in the Journal of the American Dental Association, May 2002). This becomes quite a compelling image for your patients to look at when they know their risk score and you are recommending treatment to prevent this kind of outcome. We've prepared a printable sheet for you to show to patients with this graph, and would be happy to email it to you, branded with your practice name if you wish - request this graph now.
Simple scripts available
We've developed some simple example scripts for conversations you may have with patients about PreViser or related topics - things like how to introduce a patient to PreViser, how to explain their perio disease description, etc. These are meant as samples for you to use in your own style, but we've had good feedback that these clearly summarize and communicate great points to make with patients. We'd be happy to send you these scripts by email - ask for the free scripts today!
Friday, March 13, 2009
Interceptive Medicine: the Paradigm Beyond Preventive Medicine
By Dr. Randy Nolf, from Feb 16, 2009.
The cost of medical care is spiraling toward a crisis, and is perhaps already beyond crisis. The rise toward 20% of the gross domestic product is unsustainable and seriously jeopardizes the U.S.A.’s ability to compete in a global economy.
How can we control it? One way is to control utilization and the cost of utilization, by rationing care and reducing fees. Have less providers and technology than demand, forcing extended waiting times. Make insurance authorization difficult and time-consuming. Artificially lower fees. This would control costs by choking down utilization, and is obviously not a desirable means to that end.
Another approach is from the “need” side. Lower the demand for utilization by lowering the need for advance reparative procedures. “Prevention”? I don't think so. Prevention has severe inefficiencies and is fraught with potential for overuse, minimizing the return on investment and it doesn't inspire most patients to take action based only on a variable “risk guess” of a future possibility. For instance, inflammatory periodontitis will have a different diagnosis or explanation from different doctors and hygienists. One office doesn't even mention it, another says there's "bone loss or a pocket", another says "there might be a problem, we'll watch it," and then there's the office that paints a picture of dire consequences of bone loss tooth loss and potential for heart disease with increased risk of dementia. If I was the patient, I'd keep shopping until I found the diagnosis I liked. An alternate concept to “prevention,” to lower cost of care while improving quality, is Interceptive Medicine. To intercept means “to stop or interrupt the course, progress, or transmission of.” Metrics are required to standardize quantification of the present state of disease, and to accurately, objectively and reproducibly score the risk of progression or onset of the disease.
There is a definite distinction between prevention and interception. Prevention is like crop dusting: i.e., treating 100% of the plants on hundreds of acres to protect the 20% that will get bugs. Simplistically, we may think of a car. Prevention could be changing the oil every 500 miles. It will almost certainly increase the life of the engine over not changing the oil, but is rarely necessary or cost-effective beyond standard maintenance intervals...unless you're running the Baja. The trick in medicine is to identify all those patients who are the medical equivalent of “running the Baja.” These patients are on a trajectory to onset or progression of disease and can be treated interceptively when appropriately identified.
The delivery platform for Interceptive Medicine is established, proven reliable, and delivered globally by the PreViser Corporation. The first disease entity to be addressed with this analytic system is inflammatory periodontal disease.
Interceptive medicine is the next logical progression of medical care, not more high-tech, high-cost, and invasive repair. The paradigm requires easy-to-use, inexpensive, computer-driven, objective, reproducible programs to score disease severity and risk. Simple numeric scoring will enable physicians of all specialties, plus auxiliary staff such as nurses, nurse practitioners and physicians assistants, to uniformly assess disease. Once uniformly scored, "best practice" treatments can be uniformly applied and outcomes measured. This is not possible with the current system, and yet the technology exists for disease specific tools to be quickly developed and rapidly deployed.
Consider the impact of applying the concept to cardiovascular disease, which causes more deaths than all the cancers combined. Annual costs of cardiovascular disease, including indirect costs, are $450 billion in the U.S. and $300 billion in Europe. It is estimated that effective interceptive measures could lower the costs of treatment by 30%. That's enough to grab policymakers' attention, even in this day of massive multi-hundreds-of-billion-dollar bail-outs.
Dentists may well lead the way to this new era of healthcare by adopting PreViser disease management practices, and establishing a policy of practice-wide perio diagnosis and risk assessment. Costs are minimal and rewards are high for both patient and doctor.
Cost containment will be a theme in medicine and dentistry for the foreseeable future. It will be far more palatable to drive containment from the need side than to be forced to accept utilization control measures set by government or insurance companies with the primary measure being reduced expenditures.
Dentists have a choice: they can lead this parade or be left to sweep up after the elephants.
The cost of medical care is spiraling toward a crisis, and is perhaps already beyond crisis. The rise toward 20% of the gross domestic product is unsustainable and seriously jeopardizes the U.S.A.’s ability to compete in a global economy.
How can we control it? One way is to control utilization and the cost of utilization, by rationing care and reducing fees. Have less providers and technology than demand, forcing extended waiting times. Make insurance authorization difficult and time-consuming. Artificially lower fees. This would control costs by choking down utilization, and is obviously not a desirable means to that end.
Another approach is from the “need” side. Lower the demand for utilization by lowering the need for advance reparative procedures. “Prevention”? I don't think so. Prevention has severe inefficiencies and is fraught with potential for overuse, minimizing the return on investment and it doesn't inspire most patients to take action based only on a variable “risk guess” of a future possibility. For instance, inflammatory periodontitis will have a different diagnosis or explanation from different doctors and hygienists. One office doesn't even mention it, another says there's "bone loss or a pocket", another says "there might be a problem, we'll watch it," and then there's the office that paints a picture of dire consequences of bone loss tooth loss and potential for heart disease with increased risk of dementia. If I was the patient, I'd keep shopping until I found the diagnosis I liked. An alternate concept to “prevention,” to lower cost of care while improving quality, is Interceptive Medicine. To intercept means “to stop or interrupt the course, progress, or transmission of.” Metrics are required to standardize quantification of the present state of disease, and to accurately, objectively and reproducibly score the risk of progression or onset of the disease.
There is a definite distinction between prevention and interception. Prevention is like crop dusting: i.e., treating 100% of the plants on hundreds of acres to protect the 20% that will get bugs. Simplistically, we may think of a car. Prevention could be changing the oil every 500 miles. It will almost certainly increase the life of the engine over not changing the oil, but is rarely necessary or cost-effective beyond standard maintenance intervals...unless you're running the Baja. The trick in medicine is to identify all those patients who are the medical equivalent of “running the Baja.” These patients are on a trajectory to onset or progression of disease and can be treated interceptively when appropriately identified.
The delivery platform for Interceptive Medicine is established, proven reliable, and delivered globally by the PreViser Corporation. The first disease entity to be addressed with this analytic system is inflammatory periodontal disease.
Interceptive medicine is the next logical progression of medical care, not more high-tech, high-cost, and invasive repair. The paradigm requires easy-to-use, inexpensive, computer-driven, objective, reproducible programs to score disease severity and risk. Simple numeric scoring will enable physicians of all specialties, plus auxiliary staff such as nurses, nurse practitioners and physicians assistants, to uniformly assess disease. Once uniformly scored, "best practice" treatments can be uniformly applied and outcomes measured. This is not possible with the current system, and yet the technology exists for disease specific tools to be quickly developed and rapidly deployed.
Consider the impact of applying the concept to cardiovascular disease, which causes more deaths than all the cancers combined. Annual costs of cardiovascular disease, including indirect costs, are $450 billion in the U.S. and $300 billion in Europe. It is estimated that effective interceptive measures could lower the costs of treatment by 30%. That's enough to grab policymakers' attention, even in this day of massive multi-hundreds-of-billion-dollar bail-outs.
Dentists may well lead the way to this new era of healthcare by adopting PreViser disease management practices, and establishing a policy of practice-wide perio diagnosis and risk assessment. Costs are minimal and rewards are high for both patient and doctor.
Cost containment will be a theme in medicine and dentistry for the foreseeable future. It will be far more palatable to drive containment from the need side than to be forced to accept utilization control measures set by government or insurance companies with the primary measure being reduced expenditures.
Dentists have a choice: they can lead this parade or be left to sweep up after the elephants.
Wednesday, March 11, 2009
PreViser and Oral Cancer
By Carl Loeb, PreViser CEO, March 10, 2009.
PreViser’s oral cancer risk analysis calculates a score on a 1 to 5 (very low to very high) scale. It takes into account various types of tobacco usage, levels of alcohol consumption, cancer history, and other factors to determine relative risk levels.
PreViser’s oral cancer risk analysis calculates a score on a 1 to 5 (very low to very high) scale. It takes into account various types of tobacco usage, levels of alcohol consumption, cancer history, and other factors to determine relative risk levels.
Many PreViser practices are now utilizing additional diagnostic technologies like Vizilite™ and Velscope™ that incorporate luminescing technology to assist in the identification of lesions that may escape identification under white light illumination.
Where these additional diagnostics represent an additional cost to the patient, it may be useful to link the decision on whom to recommend the additional procedure to the individual’s risk level for oral cancer. This may be an approach that makes sense to the patient who has to pay for the diagnostic.
The approach is simple. Here is the language that appears on the PreViser oral cancer risk patient report:
Where these additional diagnostics represent an additional cost to the patient, it may be useful to link the decision on whom to recommend the additional procedure to the individual’s risk level for oral cancer. This may be an approach that makes sense to the patient who has to pay for the diagnostic.
The approach is simple. Here is the language that appears on the PreViser oral cancer risk patient report:
Enhanced screening for oral cancer using technology designed for the purpose may be recommended by your dental professional. An examination with enhanced diagnostics may be repeated at 3 to 5 year intervals when risk is 1 or 2. A 2-year frequency may be recommended when risk is 3 or 4, or for those who are sexually active and may experience exposure to Human Papilloma virus. Patients at the highest risk level, which is 5, may have an enhanced examination annually. Should these examinations indicate suspicious lesions, further tests including biopsy may be indicated.
This recommendation refers only to ‘Enhanced screening,’ that is, additional diagnostics and not the standard oral cancer evaluation that is presumed to be included in every periodic oral evaluation.
This simple approach can significantly increase patient acceptance of the need for additional diagnostics because it connects the diagnostic to the individual risk level of the patient.
For more information on PreViser, or to schedule a private webcast explaining the technology to you or your staff, please contact us.
This recommendation refers only to ‘Enhanced screening,’ that is, additional diagnostics and not the standard oral cancer evaluation that is presumed to be included in every periodic oral evaluation.
This simple approach can significantly increase patient acceptance of the need for additional diagnostics because it connects the diagnostic to the individual risk level of the patient.
For more information on PreViser, or to schedule a private webcast explaining the technology to you or your staff, please contact us.
Sunday, March 1, 2009
PreViser Corporation and MacPractice Announce Cooperation Agreement
Press release from Feb 23, 2009.
MOUNT VERNON, Wash., and LINCOLN, Neb., Feb. 23 -- PreViser Corporation (previser.com), a world leader in risk and disease analytic software designed to enhance treatment planning for patients affected by oral disease, today announced a cooperation agreement with MacPractice, Inc. (macpractice.com), the nation's leading provider of dental practice management software running on the Macintosh computer platform. The agreement will involve cooperation in joint marketing and promotional activities and the integration of PreViser analytic technology into MacPractice DDS 3.6, making MacPractice the only native Mac-compatible practice management software to integrate the PreViser toolset.
PreViser CEO Carl Loeb noted, "While Macintosh users represent a subset of computer users, they tend to be technically adept users who welcome innovation. We are very excited about the opportunity to work with MacPractice in showing users of their software how PreViser can help enhance practice revenue, increase productivity, and enhance clinical outcomes while increasing patient satisfaction and loyalty."
Read the full release here.
Subscribe to:
Posts (Atom)
